gp120 CD4 Binding Site Profiling for HIV Antibody Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV therapies face challenges due to drug resistance, long-term toxicity, and patient adherence issues, and identifying patients susceptible to CD4 binding site-directed antibodies is limited by the need to target specific HIV species.
Innovation Solution
A method to identify HIV-infected individuals by detecting specific amino acid residues in gp120 and using antibodies or antigen-binding fragments that target the CD4 binding site (CD4bs) region, utilizing VH and VL regions with defined CDR sequences to determine susceptibility to HIV therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HIV therapies target reverse transcriptase, protease enzymes, and integrase, then HIV infection can be treated, but drug resistance develops and long-term toxicity occurs
Solution Approach 1:
The patent changes the target parameter from intracellular viral enzymes (reverse transcriptase, protease, integrase) to the extracellular gp120 envelope protein's CD4 binding site. This parameter change allows therapy to act on a different viral component that is accessible from outside the cell, avoiding the development of resistance against intracellular targets and reducing toxicity from long-term intracellular drug exposure.
Solution Approach 2:
The patent uses CD4 binding site-directed antibodies as intermediary molecules that bind to gp120 on the viral surface. These antibodies serve as mediators that block HIV entry into CD4+ cells without requiring the virus to internalize the drug, thereby preventing resistance development and reducing cellular toxicity.
2Reliability
If daily dosing regimens are used for HIV therapy, then viral infection can be controlled, but patient adherence becomes difficult to maintain
Solution Approach 1:
The patent identifies patients in advance who are likely to respond to CD4bs-directed antibodies by detecting specific amino acid residues (I201 and F353) in their gp120. This preliminary identification allows for pre-treatment planning and selection of appropriate patients before infection establishes, potentially eliminating the need for long-term daily dosing adherence.
Solution Approach 2:
The patent creates a diagnostic copy or proxy (the amino acid sequence detection) that predicts therapeutic response without requiring the patient to actually undergo the full therapy regimen. This copying approach allows identification of suitable patients based on their viral characteristics rather than requiring observation of therapeutic response over time.
3Reliability
If therapy targets specific HIV species, then therapeutic efficacy is improved, but identifying suitable patients becomes limited
Solution Approach 1:
The patent focuses on a specific local region (CD4 binding site) of the gp120 protein and identifies patients based on the amino acid sequence at this localized area (residues I201 and F353). This local quality approach allows for specific patient identification without requiring analysis of the entire viral genome, making the process more versatile and applicable to different patient populations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of patients likely to benefit from CD4bs-targeting antibodies, enhancing therapeutic efficacy and overcoming resistance and adherence issues.
Implementation Method 1
an antibody or antigen-binding fragment thereof that comprises VH and VL regions that bind to an epitope or region of gp120 in the CD4 binding site (CD4bs)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.